Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > BUSINESS
BUSINESS
- “Sales, Shares Will Follow” Tohoku ALC Opening: Mediceo President Choufuku
June 19, 2012
- DSP Obtains Approval for Antipsychotic Drug Latuda in Canada
June 19, 2012
- Pfizer Japan Top Choice in All Factors Doctors Consider Important When Prescribing Generics: QLife Survey
June 19, 2012
- Takeda to Cease Distribution of 13 former Wyeth Products, Except for Prevenar, BeneFIX, Enbrel
June 19, 2012
- [Data] Sales of Takeda’s Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Otsuka HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Astellas's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Daiichi Sankyo's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Eisai's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Mitsubishi Tanabe's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Dainippon Sumitomo's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Taisho HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Shionogi's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Ono's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Santen's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kyorin HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kaken's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Mochida's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Nippon Shinyaku's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kissei's Mainstay Products in FY2011
June 19, 2012
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…